๋ณธ๋ฌธ์œผ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ

ยฉ 2026 Molayo

X์š”์•ฝ2026. 06. 16. 08:01

๐Ÿšจํ•œ๊ตญ ๊ณผํ•™์ž๋“ค์ด ๋Œ€์žฅ์•”์„ ์—ญ์ „์‹œ์ผฐ๋‹ค! ์•”์„ธํฌ๋ฅผ ์ฃฝ์ด์ง€ ์•Š๊ณ  ๊ฑด๊ฐ•ํ•œ ์„ธํฌ๋กœ ์ „ํ™˜ํ–ˆ๋‹ค๐Ÿงฌ๐Ÿ”ฌ

์š”์•ฝ

KAIST ์กฐ๊ด‘ํ˜„ ๊ต์ˆ˜ํŒ€์ด BENEIN ํ”„๋ ˆ์ž„์›Œํฌ๋ฅผ ํ†ตํ•ด ๋Œ€์žฅ์•” ์„ธํฌ๋ฅผ ๊ฑด๊ฐ•ํ•œ ์„ธํฌ๋กœ ์žฌํ”„๋กœ๊ทธ๋ž˜๋ฐํ•˜๋Š” ๋ฐ ์„ฑ๊ณตํ–ˆ์Šต๋‹ˆ๋‹ค. ๋””์ง€ํ„ธ ํŠธ์œˆ ๊ธฐ์ˆ ๊ณผ ์œ ์ „์ž ์กฐ์ ˆ ๋„คํŠธ์›Œํฌ ๋ชจ๋ธ๋ง์„ ํ™œ์šฉํ•˜์—ฌ ์•”์„ธํฌ์˜ ์šด๋ช…์„ ์—ญ์ „์‹œํ‚ค๋Š” ์ƒˆ๋กœ์šด ํŒจ๋Ÿฌ๋‹ค์ž„์„ ์ œ์‹œํ–ˆ์Šต๋‹ˆ๋‹ค.

ํ•ต์‹ฌ ํฌ์ธํŠธ

  • BENEIN ํ”„๋ ˆ์ž„์›Œํฌ๋ฅผ ํ†ตํ•œ ์•”์„ธํฌ ์žฌํ”„๋กœ๊ทธ๋ž˜๋ฐ ์„ฑ๊ณต
  • MYB, HDAC2, FOXA2 ์œ ์ „์ž ์กฐ์ ˆ์„ ํ†ตํ•œ ์•”์„ธํฌ ์—ญ์ „
  • In vivo ์‹คํ—˜ ๊ฒฐ๊ณผ ์ข…์–‘ ํฌ๊ธฐ ์•ฝ 70% ์ถ•์†Œ ํ™•์ธ
  • BioRevert Inc.๋กœ์˜ ๊ธฐ์ˆ  ์ด์ „ ์™„๋ฃŒ ๋ฐ ์ž„์ƒ ์ค€๋น„

๐Ÿšจํ•œ๊ตญ ๊ณผํ•™์ž๋“ค์ด ๋Œ€์žฅ์•”์„ ์—ญ์ „์‹œ์ผฐ๋‹ค! ์•”์„ธํฌ๋ฅผ ์ฃฝ์ด์ง€ ์•Š๊ณ  ๊ฑด๊ฐ•ํ•œ ์„ธํฌ๋กœ ์ „ํ™˜ํ–ˆ๋‹ค๐Ÿงฌ๐Ÿ”ฌ

KAIST(ํ•œ๊ตญ๊ณผํ•™๊ธฐ์ˆ ์›)์˜ ์กฐ๊ด‘ํ˜„ ๊ต์ˆ˜ํŒ€์ด ํ™”ํ•™ ์š”๋ฒ•(chemotherapy), ์ˆ˜์ˆ  ๋˜๋Š” ๋ฐฉ์‚ฌ์„  ์—†์ด ๋Œ€์žฅ์•” ์„ธํฌ๋ฅผ ๊ฑด๊ฐ•ํ•œ ๋Œ€์žฅ ์„ธํฌ๋กœ ์ „ํ™˜ํ•˜๋Š” ๋ฐ ์„ฑ๊ณตํ–ˆ์Šต๋‹ˆ๋‹ค!

์ด๋Š” ๊ธฐ์กด์˜ "์•”์„ธํฌ๋ฅผ ์ฃฝ์—ฌ๋ผ"๋ผ๋Š” ์ ‘๊ทผ ๋ฐฉ์‹๊ณผ๋Š” ์™„์ „ํžˆ ๋‹ค๋ฅธ ํŒจ๋Ÿฌ๋‹ค์ž„์ž…๋‹ˆ๋‹ค: ์•”์„ธํฌ๋ฅผ ์žฌํ”„๋กœ๊ทธ๋ž˜๋ฐํ•˜๋Š” ๊ฒƒ(cancer reversion / reprogrammable cancer therapy).

์–ด๋–ป๊ฒŒ ์„ฑ๊ณตํ–ˆ๋‚˜? BENEIN์„ ์ด์šฉํ•œ ๋””์ง€ํ„ธ ํŠธ์œˆ(Digital Twin) ์ ‘๊ทผ ๋ฐฉ์‹

์—ฐ๊ตฌํŒ€์€ ๋‹จ์ผ ์„ธํฌ ์ „์‚ฌ์ฒด(single-cell transcriptomic) ๋ฐ์ดํ„ฐ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์œ ์ „์ž ์กฐ์ ˆ ๋„คํŠธ์›Œํฌ์˜ ๋ถˆ๋ฆฌ์–ธ ๋„คํŠธ์›Œํฌ ๋ชจ๋ธ(Boolean network model)์„ ๊ตฌ์ถ•ํ•˜๋Š” ๋…์ฐฝ์ ์ธ ๊ณ„์‚ฐ ํ”„๋ ˆ์ž„์›Œํฌ๋ฅผ ๊ฐœ๋ฐœํ–ˆ์Šต๋‹ˆ๋‹ค: BENEIN (Boolean Network Inference and Control).

์ด "๋””์ง€ํ„ธ ํŠธ์œˆ"๊ณผ ์œ ์‚ฌํ•œ ์‹œ์Šคํ…œ์€:

โœ… ์ •์ƒ ๋Œ€์žฅ ์„ธํฌ์˜ ๋ถ„ํ™” ๊ฒฝ๋กœ(differentiation trajectories)๋ฅผ ๋ชจ๋ธ๋งํ•ฉ๋‹ˆ๋‹ค.
โœ… ์–ดํŠธ๋ž™ํ„ฐ ๊ฒฝ๊ด€(Attractor landscape) ๋ถ„์„์„ ํ†ตํ•ด ํ•ต์‹ฌ ๋ถ„์ž ์กฐ์ ˆ์ž(master regulators)๋ฅผ ์ฐพ์•„๋ƒ…๋‹ˆ๋‹ค.
โœ… ์ด ์กฐ์ ˆ์ž๋“ค์„ ์กฐ์ž‘ํ•˜์—ฌ ์•”์„ธํฌ์˜ ์šด๋ช…์„ ์—ญ์ „์‹œํ‚ต๋‹ˆ๋‹ค.

๋ฐœ๊ฒฌ๋œ 3๊ฐ€์ง€ ํ•ต์‹ฌ ์œ ์ „์ž/๋งˆ์Šคํ„ฐ ์กฐ์ ˆ์ž(master regulator):

MYB
HDAC2
FOXA2

์ด ์„ธ ์œ ์ „์ž๋ฅผ ๋™์‹œ์— ์–ต์ œ(knockdown /inhibition)ํ–ˆ์„ ๋•Œ, ๋Œ€์žฅ์•” ์„ธํฌ๋Š” ์ •์ƒ ์—”ํ…Œ๋กœ์‚ฌ์ดํŠธ(enterocyte, ์žฅ๋ฒฝ ์„ธํฌ)์˜ ํŠน์„ฑ์„ ๊ฐ–๊ฒŒ ๋ฉ๋‹ˆ๋‹ค: ํ†ต์ œ๋˜์ง€ ์•Š๋Š” ์ฆ์‹์ด ๋ฉˆ์ถ”๊ณ , ๊ฑด๊ฐ•ํ•œ ์„ธํฌ ๋งˆ์ปค๊ฐ€ ๋‚˜ํƒ€๋‚˜๋ฉฐ, ์•…์„ฑ(malignant) ํŠน์„ฑ์ด ์‚ฌ๋ผ์ง‘๋‹ˆ๋‹ค.

์‹คํ—˜์  ๊ฒ€์ฆ (์‹ฌ์ธต ์—ฐ๊ตฌ ๊ฒฐ๊ณผ)

โœ…In vitro (์ฒด์™ธ ์‹คํ—˜): ์„ธ ๊ฐ€์ง€ ์„œ๋กœ ๋‹ค๋ฅธ ๋Œ€์žฅ์•” ์„ธํฌ์ฃผ์—์„œ ์ฆ์‹ (proliferation)์ด ํ˜„์ €ํžˆ ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
โœ…ํ™˜์ž ์œ ๋ž˜ ์˜ค๊ฐ€๋…ธ์ด๋“œ (Patient-derived organoids): ์„œ์šธ๋Œ€ํ•™๊ต (Seoul National University)์™€์˜ ํ˜‘๋ ฅ์„ ํ†ตํ•ด ์‹ค์ œ ํ™˜์ž ์กฐ์ง์—์„œ ์ถ”์ถœํ•œ ์˜ค๊ฐ€๋…ธ์ด๋“œ์—์„œ๋„ ์—ญ์ „ (reversion) ํ˜„์ƒ์ด ํ™•์ธ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
โœ…In vivo (์ƒ์ฒด ๋‚ด ์‹คํ—˜, ๋™๋ฌผ ๋ชจ๋ธ): ์žฌํ”„๋กœ๊ทธ๋ž˜๋ฐ๋œ ์„ธํฌ๋กœ ํ˜•์„ฑ๋œ ์ข…์–‘์€ ์•ฝ 70% ์ถ•์†Œ๋˜์—ˆ์œผ๋ฉฐ, ํ˜„๋ฏธ๊ฒฝ ๊ด€์ฐฐ ์‹œ ์ •์ƒ ์กฐ์ง๊ณผ ๋งค์šฐ ์œ ์‚ฌํ•œ ๋ชจ์Šต์„ ๋ณด์˜€์Šต๋‹ˆ๋‹ค.
โœ…์ „์‚ฌ์ฒด ๋น„๊ต (Transcriptome comparison): 400๋ช… ์ด์ƒ์˜ ๋Œ€์žฅ์•” ํ™˜์ž ์กฐ์ง ๋ฐ์ดํ„ฐ์™€ ๋น„๊ตํ–ˆ์„ ๋•Œ, ์žฌํ”„๋กœ๊ทธ๋ž˜๋ฐ๋œ ์„ธํฌ์˜ ์œ ์ „์ž ๋ฐœํ˜„ ํ”„๋กœํŒŒ์ผ (gene expression profile)์€ ์ •์ƒ ์„ธํฌ์— ๊ทผ์ ‘ํ–ˆ์Šต๋‹ˆ๋‹ค.

๋ณธ ์—ฐ๊ตฌ๋Š” Advanced Science ํ•™์ˆ ์ง€์— ๊ฒŒ์žฌ๋˜์—ˆ์Šต๋‹ˆ๋‹ค (2024๋…„ ๋ง / 2025๋…„ ์ดˆ). ์—ฐ๊ตฌํŒ€์€ ๋˜ํ•œ BioRevert Inc. ์‚ฌ์— ๊ธฐ์ˆ  ์ด์ „์„ ์™„๋ฃŒํ•˜์—ฌ ์ž„์ƒ ์ ์šฉ์„ ์œ„ํ•œ ๊ณผ์ •์„ ์‹œ์ž‘ํ–ˆ์Šต๋‹ˆ๋‹ค.

์™œ ์ดํ† ๋ก ํ˜์‹ ์ ์ธ๊ฐ€?

์ „ํ†ต์ ์ธ ์น˜๋ฃŒ๋ฒ•์€ ์•”์„ธํฌ๋ฅผ ํŒŒ๊ดดํ•˜๋Š” ๋ฐ ์ง‘์ค‘ํ•ฉ๋‹ˆ๋‹ค โ†’ ๋ถ€์ž‘์šฉ, ๋‚ด์„ฑ ๋ฐœ๋‹ฌ, ์žฌ๋ฐœ (recurrence) ์œ„ํ—˜์ด ๋†’์Šต๋‹ˆ๋‹ค.

๋ฐ˜๋ฉด, ์ด ์ƒˆ๋กœ์šด ์ ‘๊ทผ ๋ฐฉ์‹์€ ์„ธํฌ์˜ ์ •์ฒด์„ฑ์„ ๋ณ€ํ™”์‹œ์ผœ ์•”์„ "๋˜๋Œ๋ฆฝ๋‹ˆ๋‹ค". ๋ถ€์ž‘์šฉ์€ ์ตœ์†Œํ™”ํ•˜๋ฉด์„œ ๊ฑด๊ฐ•ํ•œ ์กฐ์ง์„ ๋ณด์กดํ•ฉ๋‹ˆ๋‹ค.

์กฐ๊ด‘ํ˜„ ๊ต์ˆ˜(Prof. Kwang-Hyun Cho)๊ฐ€ ๊ฐ•์กฐํ–ˆ๋“ฏ์ด: "์•”์„ธํฌ๋ฅผ ์ •์ƒ ์„ธํฌ๋กœ ์ „ํ™˜ํ•  ์ˆ˜ ์žˆ๋‹ค๋Š” ๊ฒƒ์€ ๋†€๋ผ์šด ํ˜„์ƒ์ž…๋‹ˆ๋‹ค. ์ด ์—ฐ๊ตฌ๋Š” ์•” ์—ญ์ „ (cancer reversion)์„ ์ฒด๊ณ„์ ์œผ๋กœ ์œ ๋„ํ•  ์ˆ˜ ์žˆ์Œ์„ ์ฆ๋ช…ํ•ฉ๋‹ˆ๋‹ค."

BENEIN ํ”„๋ ˆ์ž„์›Œํฌ๋Š” ๋Œ€์žฅ์•”์—๋งŒ ๊ตญํ•œ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค. ๋‹ค๋ฅธ ์•” ์œ ํ˜• ๋ฐ ์„ธํฌ ๋ถ„ํ™” ๊ณผ์ •์—๋„ ์ ์šฉ ๊ฐ€๋Šฅํ•œ ์ž ์žฌ๋ ฅ์„ ๊ฐ€์ง€๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

๋ฏธ๋ž˜์—๋Š” ์–ด๋–ค ๋ณ€ํ™”๊ฐ€ ์˜ฌ๊นŒ์š”?

์ด ๋ฐœ๊ฒฌ์€ ์•” ์—ญ์ „ ์น˜๋ฃŒ (cancer reversion therapy)๋ผ๋Š” ๊ฐœ๋…์„ ๊ตฌ์ฒดํ™”ํ•ฉ๋‹ˆ๋‹ค. ํ–ฅํ›„ ํ‘œ์  ์†Œ๋ถ„์ž ์–ต์ œ์ œ (targeted small molecule inhibitors) ๋˜๋Š” ์œ ์ „์ž ํŽธ์ง‘ ๋„๊ตฌ (CRISPR ๋“ฑ)๋ฅผ ํ†ตํ•ด ์ด๋Ÿฌํ•œ ์Šค์œ„์น˜๋“ค์„ ์ž„์ƒ์—์„œ ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์ด ๊ฐ€๋Šฅํ•ด์งˆ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๋ถ€์ž‘์šฉ์ด ์—†๊ณ , ๋” ํšจ๊ณผ์ ์ด๋ฉฐ, ๊ฐœ์ธ ๋งž์ถคํ™”๋œ ์น˜๋ฃŒ์˜ ๊ธธ์ด ์—ด๋ฆฌ๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

์•”์„ธํฌ๋ฅผ "์ฃฝ์ด๋Š”" ๋Œ€์‹  "์žฌํ”„๋กœ๊ทธ๋ž˜๋ฐ"ํ•˜๋Š” ์ด ์ ‘๊ทผ ๋ฐฉ์‹์ด ์•” ์น˜๋ฃŒ์— ์–ด๋–ค ํ˜๋ช…์„ ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ๋‹ค๊ณ  ์ƒ๊ฐํ•˜์‹œ๋‚˜์š”? ๋‹ค๋ฅธ ์•” ์œ ํ˜•์—๋„ ์ ์šฉ์ด ๊ฐ€๋Šฅํ• ๊นŒ์š”? BENEIN๊ณผ ๊ฐ™์€ ๊ณ„์‚ฐ ๋„๊ตฌ(computational tools)๊ฐ€ ์ƒ๋ฌผํ•™์—์„œ ์ˆ˜ํ–‰ํ•˜๋Š” ์—ญํ• ์— ๋Œ€ํ•ด ์–ด๋–ป๊ฒŒ ์ƒ๊ฐํ•˜์‹œ๋‚˜์š”?

๋Œ“๊ธ€๋กœ ์—ฌ๋Ÿฌ๋ถ„์˜ ์˜๊ฒฌ์„ ๊ณต์œ ํ•ด ์ฃผ์„ธ์š”. ์ด ํš๊ธฐ์ ์ธ ๋ฐœ๊ฒฌ์— ๋Œ€ํ•ด ํ•จ๊ป˜ ๋…ผ์˜ํ•ด ๋ด…์‹œ๋‹ค! ๐Ÿงฌ๐Ÿ”ฌ
[IMG:1]

AI ์ž๋™ ์ƒ์„ฑ ์ฝ˜ํ…์ธ 

๋ณธ ์ฝ˜ํ…์ธ ๋Š” X @kaan_alper (์ž๋™ ๋ฐœ๊ฒฌ)์˜ ์›๋ฌธ์„ AI๊ฐ€ ์ž๋™์œผ๋กœ ์š”์•ฝยท๋ฒˆ์—ญยท๋ถ„์„ํ•œ ๊ฒƒ์ž…๋‹ˆ๋‹ค. ์› ์ €์ž‘๊ถŒ์€ ์›์ €์ž‘์ž์—๊ฒŒ ์žˆ์œผ๋ฉฐ, ์ •ํ™•ํ•œ ๋‚ด์šฉ์€ ๋ฐ˜๋“œ์‹œ ์›๋ฌธ์„ ํ™•์ธํ•ด ์ฃผ์„ธ์š”.

์›๋ฌธ ๋ฐ”๋กœ๊ฐ€๊ธฐ
0

๋Œ“๊ธ€

0